Health Care

Bausch Health Solvency Remains A Concerns, Analyst Downgrades Stock
Using Weight Loss Medications Such As Wegovy, Zepbound? Psychologist Warns Of Linked Eating Disorder Risks
Cannabis Pharmaceuticals: Company With Ties To Groundbreaking Medical Developments Pursues Cannabinoid-Based Medicines
Using Weight Loss Medications Such As Wegovy, Zepbound? Psychologist Warns Of Linked Eating Disorder Risks
Cannabis Pharmaceuticals: Company With Ties To Groundbreaking Medical Developments Pursues Cannabinoid-Based Medicines
ResMed Earnings Reflect Increased Demand For Sleep Devices, Performance Indicates Positive Dynamics, Opportunities
Twist Bioscience Beats Q3 Earnings Forecast, Plans To Achieve 50% Gross Margin By Fiscal Year 2025

Health Care Recent News

Elon Musk Says Neuralink's 'First Order Of Business' Is Solving Neuron Damage 'For People…Like Stephen Hawking'
Neuralink Corp. founder Elon Musk disclosed that the primary focus of his brain-computer interface company is to address neuron damage.
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
Moderna cuts its 2024 sales forecast due to weaker demand for COVID-19 vaccines. Sales now expected between $3B-$3.5B, down from $4B. Analysts adjust price targets, citing competitive pressures from Pfizer and GSK.
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing (CORRECTED)
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins.
Vertex Pharmaceuticals Lifts Annual Guidance, Positive Growth For Its Cystic Fibrosis Franchise And Pain Management Pipeline
Vertex Pharmaceuticals reported Q2 revenues of $2.65B, near the $2.66B estimate, with an adjusted EPS loss of $(12.83), missing the $4.14 consensus. The analyst expects strong growth in the pain management market with suzetrigine.
Cannabis-Based Product Proven To Be As Effective As Melatonin For Sleep In Large-Scale Study
New study proves TruCBN as an effective, safe alternative to melatonin for improving sleep quality.
What's Going On With Eli Lilly and Company Shares Friday
Eli Lilly is anticipated to release earnings on August 8 for the 2024 fiscal year second quarter.
First-Ever Human Trial Finds CBG Reduces Anxiety And Boosts Memory
New study shows CBG may reduce anxiety and improve memory. Early findings suggest potential therapeutic benefits but more research is needed.
Alnylam Reports Q2 Earnings: What Key Metrics Have to Say
For the quarter ended June 2024, Alnylam Pharmaceuticals (NASDAQ: ALNY) reported revenue of $659.83 million, up 107% over the same period last year. EPS came in at $0.56, compared to -$2.21 in the year-ago quarter.
CONMED Q2 Earnings Beat, Sales Rise Y/Y, '24 View Cut
CONMED Corporation (NYSE: CNMD) delivered adjusted earnings per share of 98 cents in the second quarter of 2024, which beat the Zacks Consensus Estimate of 92 cents by 6.5%. The bottom line improved 18.1% from the year-ago quarter's level.
Stock Of The Day: Moderna Stock Plunges, Breaking Key Support Levels Following Earnings Report
Shares of Moderna (MRNA) have broken an important support level. This means a new downtrend may be forming.
Regeneron Tops on Q2 Earnings, Eylea HD, Dupixent Fuel Sales
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported earnings per share of $11.56, which beat the Zacks Consensus Estimate of $10.57. The company recorded an EPS of $10.24 in the year-ago period. The upside in the bottom line can be attributed to higher revenues.
Glaukos Q2 Earnings In Line, Glaucoma Drives Sales
Glaukos Corporation (NYSE: GKOS) reported second-quarter 2024 adjusted loss of 52 cents per share, in line with the Zacks Consensus Estimate. The figure was narrower than the year-ago quarter's adjusted loss of 55 cents per share.

Explore Benzinga's Financial Tools

Find Stocks Tailored to Your Trading Interests
Find Stocks Tailored to Your Trading Interests
Benzinga Pro offers a real-time newsfeed as headlines break on earnings releases, analyst ratings, rumors, the biggest movers, and many more actionable alerts.

Compare Benzinga's Favorite Brokers

Claim Exclusive Offers

Claim Exclusive Offers

Compare Benzinga's Favorite Cryptocurrency Brokers

Claim Exclusive Offers